Moderna, Inc.
MRNA
$35.61
$1.313.82%
| Weiss Ratings | MRNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | MRNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | MRNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.24 | |||
| Price History | MRNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 6.05% | |||
| 30-Day Total Return | -15.99% | |||
| 60-Day Total Return | -19.87% | |||
| 90-Day Total Return | -32.56% | |||
| Year to Date Total Return | -15.21% | |||
| 1-Year Total Return | -64.20% | |||
| 2-Year Total Return | -74.75% | |||
| 3-Year Total Return | -71.84% | |||
| 5-Year Total Return | 46.60% | |||
| 52-Week High % Change | -79.88% | |||
| 52-Week Low % Change | 17.26% | |||
| Price | MRNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $170.47 | |||
| 52-Week Low Price | $29.25 | |||
| 52-Week Low Price (Date) | Feb 14, 2025 | |||
| 52-Week High Price (Date) | May 24, 2024 | |||
| Valuation | MRNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 13.23B | |||
| Enterprise Value | 4.46B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -9.30 | |||
| Earnings Per Share Growth | -25.16% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 4.08 | |||
| Price/Book (Q) | 1.21 | |||
| Enterprise Value/Revenue (TTM) | 1.38 | |||
| Price | $35.61 | |||
| Enterprise Value/EBITDA (TTM) | -1.19 | |||
| Enterprise Value/EBIT | -1.13 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | MRNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 385.00M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | MRNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 714 6500 | |||
| Address | 325 Binney Street Cambridge, MA 02142 | |||
| Website | www.modernatx.com | |||
| Country | United States | |||
| Year Founded | 2010 | |||
| Profitability | MRNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -121.90% | |||
| Profit Margin | -110.04% | |||
| Management Effectiveness | MRNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -15.14% | |||
| Return on Equity | -- | |||
| Income Statement | MRNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 3.11B | |||
| Total Revenue (TTM) | 3.24B | |||
| Revenue Per Share | $8.41 | |||
| Gross Profit (TTM) | -2.77B | |||
| EBITDA (TTM) | -3.76B | |||
| EBIT (TTM) | -3.95B | |||
| Net Income (TTM) | -3.56B | |||
| Net Income Avl. to Common (TTM) | -3.56B | |||
| Total Revenue Growth (Q YOY) | -65.64% | |||
| Earnings Growth (Q YOY) | -616.13% | |||
| EPS Diluted (TTM) | -9.30 | |||
| EPS Diluted Growth (Q YOY) | -638.96% | |||
| Balance Sheet | MRNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 7.03B | |||
| Cash Per Share (Q) | $18.25 | |||
| Total Current Assets (Q) | 8.10B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 10.90B | |||
| Current Ratio (Q) | 3.671 | |||
| Book Value Per Share (Q) | $28.24 | |||
| Total Assets (Q) | 14.14B | |||
| Total Current Liabilities (Q) | 2.21B | |||
| Total Debt (Q) | 747.00M | |||
| Total Liabilities (Q) | 3.24B | |||
| Total Common Equity (Q) | 10.90B | |||
| Cash Flow | MRNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 1.95B | |||
| Cash from Financing (TTM) | 56.00M | |||
| Net Change in Cash (TTM) | -999.00M | |||
| Levered Free Cash Flow (TTM) | -3.09B | |||
| Cash from Operations (TTM) | -3.00B | |||
